Navigation Links
Neura Therapeutik and AIT Laboratories Partner to Promote Pain Products
Date:9/6/2012

PRINCETON, N.J. and INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Neura Therapeutik and AIT Laboratories have formed a strategic partnership to explore the possibility of co-promoting current and future analgesic products to pain specialty physicians. Under the terms of the agreement, Neura would support AIT's national sales force with its established commercial drug and development infrastructure.

In a 2011 report issued by Research and Markets, it is estimated that the U.S. market for pain management therapeutics will generate more than $40 billion annually and is expected to grow to $60 billion by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer, arthritis, migraines and back pain. "Entering into this strategic partnership allows AIT to complement our existing laboratory testing and is consistent with AIT's position as a healthcare company offering healthcare practitioners options to help them treat patients with chronic pain," said AIT President and CEO Ron Thieme, Ph.D. AIT Laboratories is a national healthcare company specializing in compliance monitoring, forensics and clinical testing.

Neura Therapeutik is a pain specialty company led by a management team with years of experience in the analgesic market that has successfully launched blockbuster drugs such as Duragesic® and Vicodin ES®. "We are very excited about the collaboration with AIT and are confident that the efforts of their sales force will strengthen the position of our analgesic product portfolio," said Neura Therapeutik CEO John LaLota. "The addition of AIT's sales force, together with the efforts of our institutional sales force, will allow us to effectively educate pain treating physicians about the scientific value and patient benefits offered by our products and those of our co-promotion partners."

Chronic pain affects an estimated 116 million adults in the U.S. -- more than the number affected by heart disease, diabetes, and cancer combined, according to a report by the Institute of Medicine. "AIT has worked with healthcare practitioners treating chronic pain for many years and we know the challenges they sometimes face in finding relief for their patients," said Thieme. "The sophisticated data we provide from our laboratory reports coupled with information about new analgesics in the market, will give healthcare practitioners additional avenues to effectively treat their patients and improve patient outcomes."

About Neura Therapeutik:
Neura Therapeutik LLC (Neura) is a pain specialty company focused on the commercialization of innovative analgesics that address unmet needs in the marketplace. Neura is divided into two strategic business units:

  • Neura Labs, LLC – Focused on the in-licensing and launch of pharmaceutical assets where Neura's development and commercial experience can be leveraged to provide value enrichment through optimal clinical development and commercial advancement.
  • Neura Group, LLC – Focused on providing an array of commercial services and management oversight that will optimize the value of market ready/currently marketed assets.
  • Please visit neuratherapeutik.com for more information.
  • About AIT Laboratories
    AIT Laboratories, headquartered in Indianapolis, Ind., is a national healthcare company that specializes in compliance testing, forensic toxicology drug testing and clinical laboratory testing. The employee-owned company is recognized nationwide for superior customer service and quality in testing. To learn more about AIT, visit AITLABS.com; follow us on Twitter and like us on Facebook.Media Contacts:Raquel Bahamonde

    Greg GirondaAIT Laboratories

    Neura Therapeutik LLC 317-308-0064

    609-256-1942rbahamonde@aitlabs.com

    girondag@neuratherapeutik.com


    '/>"/>
    SOURCE AIT Laboratories
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
    2. Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
    3. Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
    4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
    6. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
    7. Neuralstem Updates ALS Stem Cell Trial Progress
    8. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
    9. Nelson Laboratories to Present Latest FDA Trends at MEDevice Forum San Diego
    10. SureGene and PGXL Laboratories launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R)
    11. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/22/2017)... MILWAUKEE , March 22, 2017 Serve You ... Custom Prescription Management, Inc. (Serve You), based in ... Order Pharmacy (NEMOP) business, based in Middlebury, Vermont ... positioning ourselves for geographic expansion, so it was perfect timing ... , President and CEO of Serve You. "Like us, NEMOP ...
    (Date:3/22/2017)... N.J. , March 22, 2017  CANTEL MEDICAL CORP. ... B. Hansen , President and CEO, will be presenting at ... at the Westin Grand Central Hotel in New ... April 5, 2017 at 3:00 p.m. ET. In addition, management ... A live audio webcast will be available ...
    (Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
    (Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: ... with an infinitely more profound faith of God’s promise of Heaven for His people. ... who spends each day with his wife, three children and six grandchildren living and ...
    (Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful ... “A Respectful Response To Atheist Manifesto” is the creation of published author Richard ... Nancy, for sixty years. He holds graduate degrees from Kent State University and ...
    (Date:3/23/2017)... ... 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s love. ... rulers of Heaven was asked by God to write a book about Him. , She ... because I kept my commitment to the Lord God. They have not walked in my ...
    (Date:3/22/2017)... ... 2017 , ... Death anxiety is unconscious and needs understanding and non-judgmental support ... to write the book titled “ As Good as Goodbyes Get ” (published by ... what she was experiencing at the bedside of patients who were dying. The book ...
    Breaking Medicine News(10 mins):